biotechNew
Generate Biomedicines
Generative biology platform designing novel protein therapeutics
weight 0.0Flux 62▴PaidLaunched 2026-06
💸 No earnings reported yet
What it is
Boston biotech using its Chroma generative model to design entirely new protein drugs across antibodies, enzymes and vaccines. Held a ~$425M IPO in early 2026.
How AI plugs in
Generative AI trained on 160k+ structures and 190M+ sequences proposes and optimizes de novo protein therapeutics.
★ Reviews
No reviews yet — be the first.Your rating